Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Acute Non Lymphocytic Leukemia

Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors

Leukemia volume 19, pages 1751–1759 (2005)Cite this article

Abstract

Histone deacetylase inhibitors (HDIs) are a new class of drugs with significant antileukemic activity. To explore mechanisms of disease-specific HDI activity in acute myeloid leukaemia (AML), we have characterised expression of all 18 members of the histone deacetylase family in primary AML blasts and in four control cell types, namely CD34+ progenitors from umbilical cord, either quiescent or cycling (post-culture), cycling CD34+ progenitors from GCSF-stimulated adult donors and peripheral blood mononuclear cells. Only SIRT1 was consistently overexpressed (>2 fold) in AML samples compared with all controls, while HDAC6 was overexpressed relative to adult, but not neo-natal cells. HDAC5 and SIRT4 were consistently underexpressed. AML blasts and cell lines, exposed to HDIs in culture, showed both histone hyperacetylation and, unexpectedly, specific hypermethylation of H3 lysine 4. Such treatment also modulated the pattern of HDAC expression, with strong induction of HDAC11 in all myeloid cells tested and with all inhibitors (valproate, butyrate, TSA, SAHA), and lesser, more selective, induction of HDAC9 and SIRT4. The distinct pattern of HDAC expression in AML and its response to HDIs is of relevance to the development of HDI-based therapeutic strategies and may contribute to observed patterns of clinical response and development of drug resistance.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Moe-Behrens GH, Pandolfi PP . Targeting aberrant transcriptional repression in acute myeloid leukaemia. Rev Clin Exp Hematol 2003; 7: 139–159.

    CAS  PubMed  Google Scholar 

  2. Faretta M, Di Croce L, Pellici PG . Effects of the acute myeloid leukaemia-associated fusion proteins on nuclear architecture. Semin Haematol 2001; 38: 42–53.

    Article  CAS  Google Scholar 

  3. Melnick A, Licht JD . Histone deactylases as therapeutic targets in hematologic malignancies. Curr Opin Hematol 2002; 9: 322–332.

    Article  Google Scholar 

  4. De Ruijter AJM, Van Gennip AH, Caron HN, Kemp S, Van Kuilenburg ABP . Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737–749.

    Article  CAS  Google Scholar 

  5. Gregoretti IV, Lee Y-M, Goodson HV . Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004; 338: 17–31.

    Article  CAS  Google Scholar 

  6. Blander G, Guarente L . The Sir2 family of protein deacetylases. Annu Rev Biochem 2004; 73: 417–435.

    Article  CAS  Google Scholar 

  7. Gao L, Cueto MA, Asselbergs F, Atadja P . Cloning and functional characterisation of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002; 277: 25748–25755.

    Article  CAS  Google Scholar 

  8. Sengupta S, Seto E . Regulation of histone deacetylase activities. J Cell Biochem 2004; 93: 57–67.

    Article  CAS  Google Scholar 

  9. Matsuyama A, Shimazu T, Sumida Y, Saito A, Yoshimatsu Y, Seigneurin-Berny D et al. In vivo destabilization of dynamic microtubules by HDAC6 mediated deacetylation. EMBO J 2002; 21: 6820–6831.

    Article  CAS  Google Scholar 

  10. Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002; 21: 2383–2396.

    Article  CAS  Google Scholar 

  11. Luo J, Nikolaev AY, Imai S, Chen D, Su F, Shiloh A et al. Negative control of p53 by Sir2 promotes cell survival under stress. Cell 2001; 107: 137–148.

    Article  CAS  Google Scholar 

  12. Vaziri H, Dessain SK, Ng EE, Imai SI, Frye RA, Pandita TK et al. hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 2002; 107: 149–159.

    Article  Google Scholar 

  13. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303: 2011–2105.

    Article  CAS  Google Scholar 

  14. Motta MC, Divecha N, Lemieux M, Kamel C, Chen D, Gu W et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551–563.

    Article  CAS  Google Scholar 

  15. Marks PA, Richon VM, Miller T, Kelly WK . Histone deacetylase inhibitors. Adv Cancer Res 2004; 91: 137–168.

    Article  CAS  Google Scholar 

  16. Kelly WK, O’Connor OA, Marks PA . Histone deacetylase inhibitors: from target to clinical trials. Expert Opin Investig Drugs 2002; 11: 1695–1713.

    Article  CAS  Google Scholar 

  17. Barlow AL, van Drunen CM, Johnson CA, Tweedie S, Bird A, Turner BM . dSIR2 and dHDAC6: two novel, inhibitor resistant deacetylases in Drosophila melanogaster. Exp Cell Res 2001; 265: 90–103.

    Article  CAS  Google Scholar 

  18. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001; 20: 6969–6978.

    Article  CAS  Google Scholar 

  19. Turner BM, O’Neill LP, Allan IM . Histone H4 acetylation in human cells. Frequency of acetylation at different sites defined by immunolabeling with site specific antibodies. FEBS Lett 1989; 253: 141–145.

    Article  CAS  Google Scholar 

  20. White DA, Belyaev ND, Turner BM . Preparation of site specific antibodies to acetylated histones. Methods 1999; 19: 417–424.

    Article  CAS  Google Scholar 

  21. Johnson CA, White DA, Lavender JS, O’Neill LP, Turner BM . Human class I histone deacetylase complexes show enhanced catalytic activity in the presence of ATP and co-immunoprecipitate with the ATP-dependent chaperone protein Hsp70. J Biol Chem 2002; 277: 9590–9597.

    Article  CAS  Google Scholar 

  22. Drexler HG, Quentmeier H, MacLeod RAF, Uphoff CC, Hu Z-B . Leukemia cell lines: in vitro models for the study of acute promyelocytic leukaemia. Leukemia Res 1995; 19: 681–691.

    Article  CAS  Google Scholar 

  23. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA et al. The histone decetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 2003; 22: 3411–3420.

    Article  Google Scholar 

  24. Whitlock JP, Galeazzi D, Schulman H . Acetylation and calcium-dependent phosphorylation of histone H3 in nuclei from butyrate-treated HeLa cells. J Biol Chem 1983; 258: 1299–1304.

    CAS  PubMed  Google Scholar 

  25. Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T . Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004; 112: 26–32.

    Article  CAS  Google Scholar 

  26. Zhu P, Martin E, Mengwasser J, Schlag P, Janssen K-P, Gottlicher M . Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004; 5: 455–463.

    Article  CAS  Google Scholar 

  27. Araki T, Sasaki Y, Milbrandt J . Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004; 305: 1010–1013.

    Article  CAS  Google Scholar 

  28. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 2003; 100: 10794–10799.

    Article  CAS  Google Scholar 

  29. Fulco M, Schlitz RL, Iezzi S, King MT, Zhao P, Kishiwaya Y et al. Sir2 regulates skeletal muscle differentiation as a potential sensor of the redox state. Mol Cell 2003; 12: 51–62.

    Article  CAS  Google Scholar 

  30. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, Kessler B et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305: 390–396.

    Article  CAS  Google Scholar 

  31. Lachner M, O’Sullivan RJ, Jenuwein TJ . An epigenetic road map for histone lysine methylation. J Cell Sci 2003; 116: 2117–2124.

    Article  CAS  Google Scholar 

  32. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD et al. MLL targets SET domain methyltransferase activity to HOX gene promoters. Mol Cell 2002; 10: 1107–1117.

    Article  CAS  Google Scholar 

  33. Van Lint C, Emiliani S, Verdin E . The expression of a small fraction of cellular gene is changed in response to histone hyperacetylation. Gene Exp 1996; 5: 245–254.

    CAS  Google Scholar 

  34. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31: 141–149.

    Article  CAS  Google Scholar 

  35. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 3697–3702.

    Article  CAS  Google Scholar 

  36. Kyrylenko S, Kyrylenko O, Suuronen T, Salminen A . Differential regulation of the Sir2 histone deacetylase genes by inhibitors of class I and II histone deacetylases. Cell Mol Life Sci 2003; 60: 1990–1997.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Professor Paul Marks and Dr Victoria Richon (Aton Pharma Inc., New York) for generous provision of SAHA, Dorothy McDonald and Virginia Turner (National Blood Service, Birmingham) for invaluable help in the processing of primary samples, Christine James and Emma Yates for skilled technical assistance and the custodians of the National Cancer Research Network AML cell bank for access to archived material. This work was supported by the Leukaemia Research Fund (CMB, CC, BMT) and Cancer Research UK (BMT).

Author information

Author notes

  1. C A Bradbury and F L Khanim: CAB and FLK contributed equally to this work

Authors and Affiliations

  1. Institute of Biomedical Research, University of Birmingham Medical School, Birmingham, B15 2TT, UK

    C A Bradbury, D A White & B M Turner

  2. School of Biosciences, University of Birmingham, Birmingham, B15 2TH, UK

    F L Khanim, R Hayden & C M Bunce

  3. CRUK Institute of Cancer Research, University of Birmingham Medical School, Birmingham, B15 2TT, UK

    M T Drayson & C Craddock

Authors
  1. C A Bradbury
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F L Khanim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Hayden
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C M Bunce
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D A White
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M T Drayson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Craddock
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B M Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B M Turner.

Additional information

Supplementary Information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu).

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bradbury, C., Khanim, F., Hayden, R. et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 19, 1751–1759 (2005). https://doi.org/10.1038/sj.leu.2403910

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403910

Keywords

This article is cited by

Search

Advanced search

Quick links